MSC-based Therapy
Type 1 Diabetes
About Kyttaro
Kyttaro Therapeutics is a private, preclinical-stage biotech leveraging a proprietary platform of genetically modified mesenchymal stem cells (MSCs). With a foundation in 15 years of R&D and a portfolio of 58 patents, the company is advancing programs in Graft vs. Host Disease (GvHD), Type 1 Diabetes, kidney disease, and combination therapies with CAR-T. Headquartered in Munich, Kyttaro is preparing to initiate clinical trials for its lead GvHD program in Europe and the US while seeking partnerships to expand its pipeline.
View full company profileAbout Kyttaro
Kyttaro Therapeutics is a private, preclinical-stage biotech leveraging a proprietary platform of genetically modified mesenchymal stem cells (MSCs). With a foundation in 15 years of R&D and a portfolio of 58 patents, the company is advancing programs in Graft vs. Host Disease (GvHD), Type 1 Diabetes, kidney disease, and combination therapies with CAR-T. Headquartered in Munich, Kyttaro is preparing to initiate clinical trials for its lead GvHD program in Europe and the US while seeking partnerships to expand its pipeline.
View full company profileAbout Kyttaro
Kyttaro Therapeutics is a private, preclinical-stage biotech leveraging a proprietary platform of genetically modified mesenchymal stem cells (MSCs). With a foundation in 15 years of R&D and a portfolio of 58 patents, the company is advancing programs in Graft vs. Host Disease (GvHD), Type 1 Diabetes, kidney disease, and combination therapies with CAR-T. Headquartered in Munich, Kyttaro is preparing to initiate clinical trials for its lead GvHD program in Europe and the US while seeking partnerships to expand its pipeline.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |
| Type I Diabetes | Genclis | Discovery |
| Inreda AP® | Inreda Diabetic | Commercial |
| iTOL-101 | iTolerance | Preclinical |